SCHEMBL5514865

SCHEMBL5514865

[CH2]OC(=O)OC(CC)CCC

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCA P17252 2/20 0.47
PRKCD Q05655 2/20 0.47
HDAC7 Q8WUI4 1/20 0.34
HDAC8 Q9BY41 1/20 0.34
HDAC6 Q9UBN7 1/20 0.34
HDAC9 Q9UKV0 1/20 0.34
HDAC5 Q9UQL6 1/20 0.34
CTSK P43235 2/20 0.34
CHRM1 P11229 1/20 0.33
AKR1A1 P14550 1/20 0.33
CHRM3 P20309 1/20 0.33
HTR2A P28223 1/20 0.33
HTR2C P28335 1/20 0.33
ADRA1A P35348 1/20 0.33
HRH1 P35367 1/20 0.33
DRD3 P35462 1/20 0.33
SLC6A3 Q01959 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC2 Q92769 1/20 0.33
TDP1 Q9NUW8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6895132 0.91 CTSK (0.40) PRKCAPRKCDHDAC7HDAC8HDAC6
SCHEMBL348985 0.87 PRKCA (0.49) PRKCAPRKCDHDAC7HDAC8HDAC6
SCHEMBL305035 0.87 CTSK (0.34) PRKCAPRKCDCTSK
SCHEMBL21566978 0.85 PRKCA (0.47) PRKCAPRKCDHDAC7HDAC8HDAC6
SCHEMBL6507592 0.83 PRKCA (0.46) PRKCAPRKCDHDAC7HDAC8HDAC6
SCHEMBL14245197 0.83 PRKCA (0.46) PRKCAPRKCDHDAC7HDAC8HDAC6
SCHEMBL5505348 0.79 ALDH1A1 (0.48) PRKCAPRKCDCTSKCHRM1AKR1A1
SCHEMBL6893821 0.79 PRKCA (0.41) PRKCAPRKCDCTSKTDP1CYP3A4
SCHEMBL7964636 0.78 PRKCA (0.46) PRKCAPRKCDHDAC7HDAC8HDAC6
SCHEMBL4654249 0.77 CTSK (0.44) PRKCAPRKCDHDAC7HDAC8HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7157442-B2 Antibacterial compound SANKYO COMPANY, LIMITED (JP) 2007-01-02 US disclosed
EP-1209166-B1 NOVEL A-500359 DERIVATIVES SANKYO CO (JP) 2004-03-31 EP disclosed
US-20030171330-A1 Antibacterial compound SANKYO COMPANY, LIMITED (JP) 2003-09-11 US disclosed
EP-1209166-A1 NOVEL A-500359 DERIVATIVES Sankyo Company, Limited (JP) 2002-05-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030171330-A1 Antibacterial compound TLR1, MPO, O60361 PRKCA 4398/4885PRKCD 3908/4885HDAC7 1206/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.